Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
